АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ И ПРОТЕИНУРИЯ – ВАЖНЕЙШИЕ ФАКТОРЫ ПРОГРЕССИРОВАНИЯ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ
https://doi.org/10.24884/1561-6274-2004-8-1-22-28
Аннотация
Артериальная гипертензия и протеинурия – важнейшие факторы прогрессирования почечной недостаточности.
Об авторах
Н. В. Мосина
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Россия
Россия
Кафедра пропедевтики внутренних болезней, курс клинической нефрологии и диализа, факультет последипломного обучения
А. М. Есаян
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Россия
Россия
Кафедра пропедевтики внутренних болезней, курс клинической нефрологии и диализа, факультет последипломного обучения
Список литературы
1. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with endstage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753–2758
2. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long–term implications. J Am Soc Nephrol 2002; 13: S37–S40
3. Meyer KB, Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on cardiovascular disease. J Am Soc Nephrol 1998; 9 [Suppl 12]: 31–42
4. Lucas MF, Quereda C, Teruel JL et al. Effect of hypertension before beginning dialysis on survival of hemodialysis patients. Am J Kidney Dis 2003; 41 (4): 814–821
5. Adamczak M, Zeier M, Dikow R, Ritz E. Kidney and hypertension. Kidney Int 2002; 61 (80): 62
6. Palmer BF. Renal dysfunction complicating the treatment of hypertension. NEJM 2002; 347 (16): 1256–1261
7. Preston RA, Singer I, Epstein M. Renal parenchymal hypertension: current concepts of pathogenesis and management. Arch Intern Med 1996; 156 (6): 602–611
8. Шанар Ж. Почечные детерминанты сольчувствительной артериальной гипертензии. Нефрология 2002; 6 (1): 11–15
9. Guyton AC. Renal function curve: A key to understanding the pathogenesis of hypertension. Hypertens 1987; 10: 1–6
10. Keller G, Zimmer Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348: 101–108
11. Brenner BM, Chertow GM. Congenital oligonephronia and the etiology of adult hypertension and progressive renal disease. Am J Kidney Dis 1994; 23: 171–175
12. Rostand SG. Oligonephronia, primary hypertension and renal disease: ‘is the child father to the man? Nephrol Dial Transplant 2003; 18: 14341438
13. Schmid M, Meyer S, Wegner R, Ritz E. Increased genetic risk of hypertension in glomerulonephritis? J Hypertens 1990; 8: 573–577
14. Fagerudd JA, Tarnow L, Jacobsen P et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes 1998; 47: 439–444
15. Strojek K, Grzeszczak W, Morawin E et al. Nephropathy of type II diabetes: Evidence for hereditary factors? Kidney Int 1997; 51:1602–1607
16. Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877–884
17. Cameron JS, Turner DR, Ogg CS et al. The longterm prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978; 10: 213–218
18. Rossing P, Hommel E, Smidt UM, Parving H. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993; 42: 715– 719
19. Locatelli F, Marcelli D, Comelli M et al. Proteinuria and blood pressure as causal components to progression to end– stage renal failure. Nephrol Dial Transplant 1996; 11: 461–467
20. Mallick NP, Short CD, Hunt LP. How far since Ellis? The Manchester Study of glomerular disease. Nephron 1987; 46: 113–124
21. Breyer JA, Bain RP, Evans JK et al. Predictors of the progression of renal insufficiency in patients with insulin dependent diabetes and overt diabetic nephropathy. Kidney Int 1996; 50: 1651–1658
22. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754–762
23. Ruilope LM, Alcazar JM, Hernandez E et al. Does an adequate control of blood pressure protect the kidney in essential hypertension? J Hypertens 1990; 8: 525–531
24. Ruggenenti P et al. Urinary protein excretion rate is the best independent predictor of ESRF in nondiabetic proteinuric chronic nephropathies. Kidney Int 1998; 53 (5): 1209–1215
25. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646–661
26. Jafar TH, Stark PC, Schmid CH et al. Proteinuria as a modifiable risk factor for the progression of non–diabetic renal disease. Kidney Int 2001; 60 (3): 1131–1140
27. Klag MJ, Whelton PW, Bryan L et al. Blood pressure and end–stage renal disease in men. NEJM 1996; 334 (1): 13– 18
28. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285 (21): 2719–2728
29. Douglas J. Management of hypertension in high risk special populations. ASN 2002 Satellite Symposium Philadelphia, PA, November, 2002
30. Nosadini R, Tonolo G. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers. J Am Soc Nephrol 2002; 13: S216–S223
31. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448–1456
32. Wing LM, Arnolda LF, Harvey PJ et al. Low–dose diuretic and/or dietary sodium restriction when blood pressure is resistant to ACE inhibitor. Blood Press 1998; 7: 299–307
33. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin–converting–enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462
34. Hunsicker LG, Kusek JW, Striker G. for The Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood–pressure control on the progression of chronic renal disease. NEJM 1994; 330 (13): 877–884
35. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51 (6): 1908–1919
36. Praga M. Slowing the progression of renal failure. Kidney Int 2002; 61 (5): 18–27
37. Красникова ТЛ. Лозартан – блокатор ангиотензин II рецепторов: новое направление в сердечнососудистой фармакотерапии. Клиническая медицина 1996; 3: 17–21
38. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001; 345 (12): 861–869
39. Russo D, Pisani A, Balletta MM et al. Additive antiproteinuric effect of converting enzyme inhibitor and lozartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33 (5): 851–856
40. Mora–Macнa J, Cases A, Calero F, Barcelу P. Effect of angiotensin II receptor blockade on renal disease progression in patients with non–diabetic chronic renal failure. Nephrol Dial Transplant 2001; 16: 82–84
41. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321 (9): 1440–1444
42. Lewis EJ, Hunsicker LG, William R et al. Renoprotective effect of the angiotensin–receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. NEJM 2001; 345 (12): 851–860
43. Parving HH, Lehnert H, Brochner–Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 (20): 870–878
44. Nassberger J, Cugno M, Amstutz C et al. Plasma bradykinin in angio–edema. Lancet 1998; 351 (9117): 1692– 1697
45. Kincaid–Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002; 17: 597–601
46. Wright JT, Bakris JG, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421–2431
47. Holdaas H, Hartmann A, Berg KJ et al. Renal effects of losartan and amlodipine in hypertensive patients with non– diabetic nephropathy. Nephrol Dial Transplant 1998; 13 (12): 3096–3102
48. Boero R, Rollino C, Massara C et al. Verapamil versus amlodipine in proteinuric nondiabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial. J Nephrol 2001; 14: 15–18
49. Gansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood–pressure–lowering agents: A meta–analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963
50. Parving HH, Osterby R, Anderson P, Hsuech W. Diabetic nephropathy. In: Brenner B, ed. The Kidney. Philadelphia, Saunders. 1996; 1864–1892
51. Gansevoort RT, de Zeeuw D, de Jong PE. Dissociation between the course of the hemodynamic and proteinuric effects of angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 579
52. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Angiotensin II does not acutely reverse the reduction of proteinuria by long–term ACE inhibition. Kidney Int 1991; 40: 734
53. Зверев ЯФ, Брюханов ВМ. Современные представ ления о механизмах почечного действия альдостерона. Не фрология 2001; 5 (4): 9–16
54. Weber KT, Brilla CG, Campbell SE. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Research in Cardiology 1993; 88 [Suppl 1]: 107–124
55. Delyani JA, Rocha R, Cook CS et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 2001; 19 (3): 185–200
56. Pitt B, Remme W, Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEJM 2003; 348 (14): 1309–1321
57. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345 (12): 925–926
58. Struthers AD. Aldosterone: Cardiovascular assault. American Heart Journal 2002; 144 (5): S2–S7
59. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001; 37 (4): 677–688
60. Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. J Cardiac Failure 1996; 2 (1): 47–54
61. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717
62. Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renin–angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117–126
63. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12–16
64. Blasi ER, Rocha R, Rudolph AE et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63 (5): 1791–1800
65. Chobanian AV, Bakris GL, Black HR et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003; 289: 3560–3572
Рецензия
Для цитирования:
Мосина Н.В., Есаян А.М. АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ И ПРОТЕИНУРИЯ – ВАЖНЕЙШИЕ ФАКТОРЫ ПРОГРЕССИРОВАНИЯ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ. Нефрология. 2004;8(1):22-28. https://doi.org/10.24884/1561-6274-2004-8-1-22-28
For citation:
Mosina N.V., Essaian A.M. ARTERIAL HYPERTENSION AND PROTEINURIA AS THE MOST IMPORTANT FACTORS IN THE PROGRESSION OF RENAL FAILURE. Nephrology (Saint-Petersburg). 2004;8(1):22-28. (In Russ.) https://doi.org/10.24884/1561-6274-2004-8-1-22-28
Просмотров:
771
Послать статью по эл. почте 